Jaap C Reijneveld

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3476247/publications.pdf

Version: 2024-02-01

147801 149698 4,116 59 31 citations h-index g-index papers

61 61 61 7420 docs citations times ranked citing authors all docs

56

#	Article	IF	CITATIONS
1	RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics. Cancer Cell, 2015, 28, 666-676.	16.8	700
2	The application of graph theoretical analysis to complex networks in the brain. Clinical Neurophysiology, 2007, 118, 2317-2331.	1.5	494
3	DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly. Genome Research, 2014, 24, 2022-2032.	5.5	362
4	Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets. Cancer Cell, 2017, 32, 238-252.e9.	16.8	235
5	International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium. Lancet Oncology, The, 2020, 21, e83-e96.	10.7	180
6	Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. Lancet Oncology, The, 2016, 17, e510-e514.	10.7	158
7	Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis. Journal of Neuro-Oncology, 2017, 135, 183-192.	2.9	138
8	Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire. Health and Quality of Life Outcomes, 2018, 16, 114.	2.4	133
9	Epilepsy surgery outcome and functional network alterations in longitudinal MEG: A minimum spanning tree analysis. Neurolmage, 2014, 86, 354-363.	4.2	113
10	Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. Neuro-Oncology, 2017, 19, 12-21.	1.2	94
11	Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. Lancet Oncology, The, 2018, 19, 1170-1179.	10.7	80
12	Patients' Preferences for Participation in Treatment Decision-Making at the End of Life: Qualitative Interviews with Advanced Cancer Patients. PLoS ONE, 2014, 9, e100435.	2.5	79
13	ldentifying the epileptogenic zone in interictal restingâ€state <scp>MEG</scp> sourceâ€space networks. Epilepsia, 2017, 58, 137-148.	5.1	76
14	The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. Acta Neuropathologica, 2018, 135, 601-615.	7.7	76
15	The EORTC CAT Core—The computer adaptive version of the EORTC QLQ-C30 questionnaire. European Journal of Cancer, 2018, 100, 8-16.	2.8	68
16	Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review. Lancet Oncology, The, 2018, 19, e459-e469.	10.7	66
17	Seizure outcome after radiotherapy and chemotherapy in low-grade glioma patients: a systematic review. Neuro-Oncology, 2015, 17, 924-934.	1.2	65
18	Health-Related Quality of Life in Stable, Long-Term Survivors of Low-Grade Glioma. Journal of Clinical Oncology, 2015, 33, 1023-1029.	1.6	64

#	Article	IF	CITATIONS
19	Connectomic profile and clinical phenotype in newly diagnosed glioma patients. NeuroImage: Clinical, 2017, 14, 87-96.	2.7	64
20	Tumor-Educated Platelet RNA for the Detection and (Pseudo)progression Monitoring of Glioblastoma. Cell Reports Medicine, 2020, 1, 100101.	6.5	52
21	Learning of anticipatory responses in single neurons of the human medial temporal lobe. Nature Communications, 2015, 6, 8556.	12.8	48
22	The level of patient-reported outcome reporting in randomised controlled trials of brain tumour patients: A systematic review. European Journal of Cancer, 2014, 50, 2432-2448.	2.8	47
23	Internet-based guided self-help for glioma patients with depressive symptoms: a randomized controlled trial. Journal of Neuro-Oncology, 2018, 137, 191-203.	2.9	46
24	The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial. European Journal of Cancer, 2015, 51, 1321-1330.	2.8	45
25	Diagnostic Accuracy of Neuroimaging to Delineate Diffuse Gliomas within the Brain: A Meta-Analysis. American Journal of Neuroradiology, 2017, 38, 1884-1891.	2.4	42
26	Advance Care Planning in Glioblastoma Patients. Cancers, 2016, 8, 102.	3.7	39
27	Dynamic hub load predicts cognitive decline after resective neurosurgery. Scientific Reports, 2017, 7, 42117.	3.3	39
28	Localization of the Epileptogenic Zone Using Interictal MEG and Machine Learning in a Large Cohort of Drug-Resistant Epilepsy Patients. Frontiers in Neurology, 2018, 9, 647.	2.4	39
29	The association between cognitive functioning and health-related quality of life in low-grade glioma patients. Neuro-Oncology Practice, 2014, 1, 40-46.	1.6	37
30	Antiepileptic drug treatment in the end-of-life phase of glioma patients: a feasibility study. Supportive Care in Cancer, 2016, 24, 1633-1638.	2.2	34
31	Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative. Lancet Oncology, The, 2018, 19, e173-e180.	10.7	32
32	Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide. Journal of Neuro-Oncology, 2016, 126, 347-354.	2.9	31
33	Oscillatory brain activity associates with neuroligin-3 expression and predicts progression free survival in patients with diffuse glioma. Journal of Neuro-Oncology, 2018, 140, 403-412.	2.9	31
34	Impact of neurocognitive deficits on patient–proxy agreement regarding health-related quality of life in low-grade glioma patients. Quality of Life Research, 2017, 26, 869-880.	3.1	29
35	Health-Related Quality of Life or Quantity of Life: A Difficult Trade-Off in Primary Brain Tumors?. Seminars in Oncology, 2014, 41, 541-552.	2.2	25
36	CAV3 gene mutation analysis in patients with idiopathic hyper-CK-emia. Muscle and Nerve, 2006, 34, 656-658.	2.2	24

#	Article	IF	CITATIONS
37	Attitudes and preferences toward monitoring symptoms, distress, and quality of life in glioma patients and their informal caregivers. Supportive Care in Cancer, 2016, 24, 3011-22.	2.2	23
38	Epilepsy in the end of life phase of brain tumor patients: a systematic review. Neuro-Oncology Practice, 2014, 1, 134-140.	1.6	21
39	The association between preoperative edema and postoperative cognitive functioning and health-related quality of life in WHO grade I meningioma patients. Acta Neurochirurgica, 2019, 161, 579-588.	1.7	20
40	Accurate Delineation of Glioma Infiltration by Advanced PET/MR Neuro-Imaging (FRONTIER Study). Neurosurgery, 2016, 79, 535-540.	1.1	19
41	Spatial concordance of DNA methylation classification in diffuse glioma. Neuro-Oncology, 2021, 23, 2054-2065.	1.2	19
42	Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials—Letter. Clinical Cancer Research, 2016, 22, 5617-5617.	7.0	18
43	Cognitive functioning and functional brain networks in postoperative WHO grade I meningioma patients. Journal of Neuro-Oncology, 2018, 140, 605-613.	2.9	17
44	Healthcare utilization and productivity loss in glioma patients and family caregivers: the impact of treatable psychological symptoms. Journal of Neuro-Oncology, 2020, 147, 485-494.	2.9	16
45	Health-related quality of life in brain tumor patients: as an endpoint in clinical trials and its value in clinical care. Expert Review of Quality of Life in Cancer Care, 2016, 1, 37-44.	0.6	14
46	Evaluation of potential circulating biomarkers for prediction of response to chemoradiation in patients with glioblastoma. Journal of Neuro-Oncology, 2016, 129, 221-230.	2.9	13
47	Altered GABA _A receptor density and unaltered bloodâ€"brain barrier [¹¹ C]flumazenil transport in drug-resistant epilepsy patients with mesial temporal sclerosis. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 97-105.	4.3	8
48	Direct comparison of [11C] choline and [18F] FET PET to detect glioma infiltration: a diagnostic accuracy study in eight patients. EJNMMI Research, 2019, 9, 57.	2.5	8
49	Final results of the EORTC Brain Tumor Group randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1st recurrence grade II/III glioma without $1p/19q$ co-deletion Journal of Clinical Oncology, 2017, 35, 2009-2009.	1.6	8
50	EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma Journal of Clinical Oncology, 2019, 37, TPS2072-TPS2072.	1.6	6
51	Clustering of EORTC QLQ-C30 health-related quality of life scales across several cancer types: Validation study. European Journal of Cancer, 2022, 170, 1-9.	2.8	6
52	Quantification of $\langle \sup 11 \rangle$ C-Laniquidar Kinetics in the Brain. Journal of Nuclear Medicine, 2015, 56, 1730-1735.	5.0	5
53	A Web-Based Lifestyle Intervention Aimed at Improving Cognition in Patients With Cancer Returning to Work in an Outpatient Setting: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2021, 10, e22670.	1.0	3
54	Molecular genetic, host-derived and clinical determinants of long-term survival in glioblastoma: First results from the ETERNITY study (EORTC 1419) Journal of Clinical Oncology, 2019, 37, 2056-2056.	1.6	3

#	Article	IF	CITATIONS
55	Advance care planning (ACP) in glioblastoma patients: Evaluation of a disease-specific ACP program and impact on outcomes. Neuro-Oncology Practice, 2022, 9, 496-508.	1.6	3
56	Another look at floor and ceiling effects in the EORTC QLQ 30 Physical Functioning subscale and possible solutions. Cancer, 2022, 128, 2384-2385.	4.1	1
57	Psycho-oncology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 305-313.	1.8	O
58	Allowance of tumor-educated platelets for multiclass liquid biopsy-based diagnosis of cancer Journal of Clinical Oncology, 2015, 33, 11058-11058.	1.6	0
59	Effect of the European Organization for Research and Treatment of Cancer (EORTC) on social life for cancer survivors in Europe Journal of Clinical Oncology, 2016, 34, 218-218.	1.6	0